December 5, 2019 10:27 AM EST

AstraZeneca, Merck score China OK for Lynparza; Regeneron spotlights mid-stage data for rare disease drug

ENDPOINTS

→ As they continue to scoop up wins for their PARP juggernaut Lynparza, AstraZeneca — along with their partners at Merck — have scored approval in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca, Merck score China OK for Lynparza; Regeneron spotlights mid-stage data for rare disease drug

ENDPOINTS

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

As­traZeneca, Mer­ck score Chi­na OK for Lyn­parza; Re­gen­eron spot­lights mid-stage da­ta for rare dis­ease drug

ENDPOINTS

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

AstraZeneca, Merck score China OK for Lynparza; Regeneron spotlights mid-stage data for rare disease drug

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival